Next-generation treatments for metastatic breast cancer
Despite the observed effectiveness of endocrine drugs and the potential for CDK4/6 inhibitors to be used in metastatic settings, there is still a need to study drugs such as OP-1250. This necessity stems from the fact that tumors can become resistant to treatment. In addition, some endocrine drugs used after treatment with CDK4/6 inhibitors do not achieve the desired level of effectiveness.
OP-1250 is a drug that you take orally. It works by completely blocking estrogen receptors, which are involved in the growth of some types of breast cancer. It also prevents the receptors from performing their normal functions and causes them to break down. Scientists think OP-1250 may be more effective than other drugs that only partially block the receptors. Laboratory studies have shown that OP-1250 is effective against both mutant and non-mutant breast cancers. These findings have led to ongoing clinical trials to test the effectiveness of OP-1250 in patients with advanced breast cancer who have not responded to other treatments. Early results from the Phase 1 trial show that a small number of patients responded positively to the drug, with some experiencing tumor shrinkage or stabilization.
Other mechanisms by drug class:
Ongoing clinical trials of next-generation endocrine therapies in metastatic, adjuvant, and neoadjuvant settings.
refer to:
Alison D Parisian, Leslie Hodges-Gallagher, Richard Sun, Susanna Barratt, Gopinath S Palanisamy, Julia Lawrence, Pamela Klein, David C Myles, Cyrus L Harmon, Peter J Kushner. The complete estrogen receptor antagonist OP-1250 can combine with HER2 inhibition to inhibit estrogen receptor-driven cellular proliferation and shrink xenograft tumors in ER+/HER2+ breast cancer models [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-08-07.
Lloyd MR, Wander SA, Hamilton E, Razavi P, Bardia A. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. Ther Adv Med Oncol. 2022 Jul 30;14:17588359221113694. doi: 10.1177/17588359221113694. PMID: 35923930; PMCID: PMC9340905.
